London-based Charm Therapeutics secured $80 million in a Series B funding round co-led by New Enterprise Associates and DR One, aimed at advancing its menin inhibitor drug candidate targeting acute myeloid leukemia (AML). Menin inhibitors disrupt the interaction of menin and KMT2A proteins, downregulating leukemogenesis-driving genes. Charm’s candidate aims to overcome resistance issues seen with existing inhibitors like Revumenib. The investment will support clinical development planned for early 2026, reflecting strong investor confidence in Charm’s AI-driven drug discovery platform DragonFold and its therapeutic potential for treatment-resistant cancers.